UNSPSC 51161721: Sivelestat

This classification denotes a protease inhibitor with the molecular formula C20H22N2O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DWI62G0P59, chemically known as o-(p-hydroxybenzenesulfonamido)hippuric acid, pivalate (ester) but generally known as sivelestat, which bears US NIH Compound Identifier 107706. European Medicines Agency schedules Sivelestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10543MIG.

UNSPSC 51161721 Sivelestat, a Commodity code, does not align with the state and local procurement activity posted under this code. The recent opportunities span naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution through cooperative purchasing — none of which involve sivelestat, a selective neutrophil elastase inhibitor with narrow clinical application. The code shows a substantial mismatch between its nominal pharmaceutical product and the actual work being solicited by state and local buyers.

State and local issuing bodies posting opportunities under this code include county health departments (Seminole County, Florida), county government benefits administrators (Hall County, Georgia), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). Recent activity spans February through July 2026, with geographic concentration in Florida, Georgia, Texas, and the Upper Midwest. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2026), Hall County's RFQ/P for on-site pharmacy services at a county family health center serving approximately 3,005 eligible individuals (response deadline June 4, 2026), and the Minnesota MMCAP cooperative's RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with proposals due March 26, 2026. The Texas HHS Commission's April 2026 RFI regarding direct-to-manufacturer prescription programs signals state-level interest in pharmacy benefit program restructuring. Given the code's nominal scope does not match observed procurement activity, firms should verify actual code assignment during opportunity evaluation rather than rely on UNSPSC categorization alone.